A Randomized, Double-Blind (Sponsor-Open), Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Non-Japanese and Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 14 Jul 2016
At a glance
- Drugs TAK 828 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Takeda
- 12 Jul 2016 Status changed from recruiting to completed.
- 22 Apr 2016 Status changed from not yet recruiting to recruiting.
- 16 Mar 2016 New trial record